ZCUBE
9.6.2020 08:02:10 CEST | Business Wire | Press release
Zcube, Zambon Research Venture, has launched the fourth edition of Open Accelerator , the international acceleration programme dedicated to startups in the Life Sciences, which seeks to identify and accelerate the best solutions that will shape the future of health. The 2020 Call, focused on digital solutions, is running until the 20th of July. Candidates can apply on the website www.openaccelerator.it
Open Accelerator is looking for innovative, high-tech projects and startups leveraging digital technologies to improve patients’ lives . The best proposals will take part in the acceleration program with the possibility of receiving a seed investment of up to € 100,000 per project.
The 2020 Call for Solutions is preferably targeted at the therapeutic areas of the Central Nervous System and Respiratory, with a particular focus on the 4 technological macro areas: Digital Prevention, Monitoring and Therapeutics; Digital Diagnostics; Virtual Health; Clinical Trials Digitalization.
This year, in an attempt to transform the COVID-19 emergency into a growth opportunity for the healthcare system, ZCube is also presenting the Special Challenge concerning new ways of interaction among healthcare professionals, Industry and the community.
“Open Accelerator is continuing with conviction into its fourth edition, reaffirming its commitment to supporting young startups, helping to transform promising projects into concrete solutions for patients” – comments Elena Zambon, President of Zambon Spa and creator of the accelerator programme – “Digital solutions have never been such a vital support for patients and caregivers as they have at this time. We have direct experience of this through ParkinsonCare, our telenursing service with a human touch. That is why we have decided to dedicate the 2020 Call to digital initiatives. We are convinced that they will be increasingly important in tackling the challenges that lie ahead in terms of health and the system's sustainability. This programme is yet another way in which we are pursuing with conviction our commitment to improving patients' lives, integrating cure and care with a multidisciplinary approach”.
After the closure of the Call, on the 20th of July, the Open Accelerator team in collaboration with a panel of experts will select the startups which between October and November will participate in the intensive 4-week acceleration programme , consisting of tailored online and onsite sessions held in the OpenZone scientific campus just outside Milan .
By taking part in the Open Accelerator programme, the startups will have access to a vast international network of entrepreneurs, scientists, investors, Venture capitalists and Life Sciences professionals. At the end of the programme the most promising projects will be awarded a seed investment of up to € 100,000 . Finally, any possible synergies with the companies of the Zambon Group will be assessed.
“Open Accelerator 2020 Call is one of a kind both- for its focus on digital health technologies and for its pragmatic approach, strongly focused on identifying concrete proposals for delivering solutions to healthcare needs ” - says Fabrizio Conicella, General Manager and Board Member of OpenZone and Zcube - “It is only through the active engagement of existing and prospective partnerships that we will be able to maximize the potential of the proposals we receive and select with a clear objective: to offer to the market innovative solutions that currently don't exist ”.
The initiative also leverages the support of several partners, including Deloitte, Unicredit Start Lab, Premio Marzotto, IQVIA Biotech, Italian Angels for Biotech, Portolano & Cavallo, Bird&Bird, Innogest, Evoleen, HUMA, NINA Capital, and Lifeseeder. Discussions are currently underway with other potential Italian and international partners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200608005658/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
4Moving Biotech Completes Enrollment in Phase 2a INFLAM MOTION Study Evaluating First-in-class Intra-articular GLP-1 Therapy Targeting Synovitis as a Driver of Pain and Disease Progression in Knee Osteoarthritis4.8.2026 07:00:00 CEST | Press release
- INFLAM MOTION enrolled 129 patients with knee osteoarthritis associated with synovitis across Europe, the United States and Canada, targeting an inflammatory phenotype associated with structural progression in knee osteoarthritis. - One of the first randomized clinical studies designed to combine symptomatic improvement with objective imaging biomarker assessment of synovial tissue thickening and inflammation, a biological process linked to disease progression - Topline results expected by the end of December 2026 4Moving Biotech (4MB), a clinical-stage biotechnology company dedicated to developing first-in-class therapies for inflammatory knee osteoarthritis, today announced the completion of patient enrollment in INFLAM MOTION, its international Phase 2a proof-of-concept study. The trial is evaluating the efficacy and safety of 4P004, an investigational intra-articular GLP-1 receptor agonist designed to address the inflammatory mechanisms underlying both symptoms and disease progre
Lehman Brothers Treasury Considers Sale and Final Wind-Down3.8.2026 15:30:00 CEST | Press release
Lehman Brothers Treasury Co. B.V. in liquidation (“LBT”) today, through its U.S. counsel Herbert Smith Freehills Kramer (USA) LLP, announced that LBT is considering a final wind-down of its estate. In connection therewith, LBT has retained Seaport Loan Products LLC as its exclusive placement agent in connection with the potential sale of LBT’s principal remaining asset – a $19.6 billion Class 4A allowed claim against Lehman Brothers Holdings Inc. (the “LBHI Claim”). LBT expects the sale to occur, if at all, in August 2026. To the extent the LBHI Claim is sold, LBT expects to make a final distribution to the holders of its existing notes and thereafter facilitate the cancellation of those notes and the final wind down of its estate in September 2026. The foregoing is subject to further consents and authorizations and LBT retains sole discretion to abandon or otherwise discontinue any sale process at any time. Accordingly, there can be no assurances that the sale process will be conducte
ClickHouse Launches ClickHouse Labs With Andy Pavlo as VP of Database Research3.8.2026 15:30:00 CEST | Press release
Renowned database researcher will lead a new group dedicated to advancing foundational database technology and sharing its work openly with the broader community ClickHouse today announced the launch of ClickHouse Labs, a new research group led by Andy Pavlo, one of the database industry’s most prominent researchers. Dr. Pavlo joins ClickHouse as Vice President of Database Research and will build a team dedicated to advancing the state of the art in database systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803890510/en/ Andy Pavlo, VP of Database Research, ClickHouse Pavlo is an award-winning database researcher and professor at Carnegie Mellon University’s Computer Science Department. He is known throughout the database community for his work on autonomous databases, transaction processing, and large-scale data analytics. At ClickHouse, he will bring that expertise to some of the most ambitious and consequential c
EuroTeleSites Strengthens Operations One Year into Sitetracker Partnership3.8.2026 15:00:00 CEST | Press release
EuroTeleSites, one of Central and Eastern Europe's leading independent tower companies, today announced the results of its first year in partnership with Sitetracker, the leading global Asset Lifecycle Management platform. One year into the deployment, EuroTeleSites reports meaningful progress in its digital transformation, with measurable improvements in operational efficiency, cross-market transparency, and project coordination across its six-country footprint. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260727009809/en/ EuroTeleSites Strengthens Operations One Year into Sitetracker Partnership Driving Efficiency in a Complex, High-Investment Environment EuroTeleSites invests approximately 25% of its revenue into capital expenditures in 2026, funding the construction and upgrade of tower infrastructure across Central and Eastern European markets. Managing this level of scale and complexity demands robust digital support
Visa to Acquire BioCatch3.8.2026 14:30:00 CEST | Press release
BioCatch’s behavioral and device intelligence expertise expected to help detect scams, account takeovers and digital fraud before they happen Visa (NYSE: V) today announced it has signed a definitive agreement to acquire BioCatch, a leading provider of behavioral-first, multi-signal fraud intelligence, from funds advised by Permira and other shareholders for $2.4 billion in cash. The acquisition of BioCatch complements Visa’s existing cyber, fraud, risk and security solutions and is expected to help clients better protect themselves and their customers from the growing threat of account takeovers, scams, money mules and application fraud. Since its inception, BioCatch has developed innovative AI and machine learning-based solutions that analyze thousands of application, behavioral, device, and network signals—such as keystrokes, touch gestures, and device handling—to detect fraud and distinguish legitimate users from fraudsters in real time. BioCatch protects 1.8 billion devices and 76
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom